Welcome to our dedicated page for Neurosense Therapeutics SEC filings (Ticker: NRSN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NeuroSense Therapeutics Ltd. (NRSN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq. NeuroSense files current reports on Form 6-K and annual reports on Form 20-F under the Securities Exchange Act of 1934, detailing clinical, regulatory, corporate and financing developments related to its neurodegenerative disease programs.
In these filings, NeuroSense reports key milestones for its lead drug candidate PrimeC, a novel extended-release oral formulation that combines ciprofloxacin and celecoxib in a fixed dose. Recent 6-K reports have furnished press releases on topics such as FDA clearance to initiate a pivotal Phase 3 trial of PrimeC in ALS, database lock for the RoAD Phase 2 Alzheimer’s disease study, and biomarker findings indicating statistically significant reductions in Alzheimer’s disease–associated microRNAs.
Other 6-K submissions include notices and proxy statements for shareholder meetings, descriptions of private placement transactions in ordinary shares, and business updates that summarize clinical trial data, regulatory interactions with agencies like the FDA and Health Canada, and manufacturing scale-up activities. Certain 6-K reports state that they are incorporated by reference into NeuroSense’s registration statements on Form F-3 and Form S-8, which relate to securities offerings and equity compensation plans.
On Stock Titan, these filings are updated as they are released through EDGAR. AI-powered tools can help readers quickly understand the focus of each 6-K or 20-F by summarizing clinical trial disclosures, regulatory announcements, financing terms and shareholder matters. This allows investors and researchers to review NeuroSense’s official statements on the development of PrimeC in ALS and Alzheimer’s disease, corporate governance actions and capital-raising activities without reading every document in full.
NeuroSense Therapeutics reported new long-term survival data from its completed Phase 2b trial of PrimeC in amyotrophic lateral sclerosis (ALS). Patients treated continuously with PrimeC showed an estimated median survival of 36.3 months versus 21.4 months for those initially on placebo, an improvement of over 14 months and about a 70% increase in median survival. A log-rank test showed statistically significant separation between treatment arms (p = 0.0218), and a Cox model associated PrimeC with a 65% reduction in risk of death versus placebo (hazard ratio 0.35; 95% CI: 0.17–0.71; p = 0.0037). The randomized, double-blind, placebo-controlled trial in 68 ALS patients had previously demonstrated slowed disease progression and favorable safety. NeuroSense believes these survival results strengthen the case for advancing PrimeC into pivotal late-stage development.
NeuroSense Therapeutics Ltd. is asking shareholders to approve an amendment to its Articles of Association to increase its registered share capital to 200 million ordinary shares, no par value. The registered share capital is currently 90 million ordinary shares.
As of February 11, 2026, the company had approximately 39 million ordinary shares available for future issuance after accounting for outstanding options, warrants and RSU grants. The board states that the larger share pool is intended to maintain flexibility for strategic financings and other issuances to support continued development of PrimeC, including planned Phase 3 activities.
The proposal will be presented at a Special Meeting of Shareholders scheduled for March 10, 2026, at 4:00 p.m. (Israel time) in Herzliya. Shareholders of record at the close of business on February 17, 2026 are entitled to notice and to vote, and the board unanimously recommends voting in favor.
NeuroSense Therapeutics filed a Form 6-K to highlight a new Australian patent grant for its lead drug candidate PrimeC. The Australian Patent Office granted Patent No. 2022370513, covering compositions combining ciprofloxacin and celecoxib, extending patent protection for PrimeC in Australia through October 2042 and reinforcing a previously granted U.S. patent.
PrimeC is a proprietary fixed-dose, extended-release oral formulation designed to deliver ciprofloxacin and celecoxib in a synchronized way, targeting multiple disease pathways in amyotrophic lateral sclerosis (ALS) and potentially Alzheimer’s disease and other neurodegenerative conditions. NeuroSense describes PrimeC as Phase 3-ready in ALS, following positive Phase 2b results and FDA clearance of a pivotal Phase 3 protocol.
The company frames this Australian patent as part of a broader global intellectual property strategy intended to support the long-term development and potential commercialization of PrimeC across major markets.
NeuroSense Therapeutics Ltd. has filed a Form F-3 shelf registration to offer up to $150,000,000 of securities, including ordinary shares, warrants, debt securities, subscription rights and units. This base shelf also supports a Capital on Demand at-the-market program of up to $6,525,000 in ordinary shares through JonesTrading, which will receive a 3% commission on gross sales.
The filing carries forward $85,778,066 of unsold securities from a prior F-3 and deems that earlier offering terminated once this new registration is effective. NeuroSense is a clinical-stage biotech focused on neurodegenerative diseases, led by ALS candidate PrimeC, which has shown positive Phase 2b data and is being advanced toward a planned Phase 3 trial. The company notes substantial doubt about its ability to continue as a going concern, highlighting the importance of future financings under this shelf and ATM.
NeuroSense Therapeutics Ltd. filed a Form 6-K as a foreign private issuer to report that it held a Special Meeting of Shareholders on December 30, 2025. The filing states that shareholders approved certain resolutions at the meeting, but does not detail the specific matters that were voted on. The report, excluding the fourth paragraph in Exhibit 99.1, is incorporated by reference into the company’s existing registration statements on Form S-8 and Form F-3, meaning this information becomes part of those securities registration documents.
NeuroSense Therapeutics Ltd. reported that the database has been locked for its proof-of-concept, Phase 2 RoAD study of PrimeC in Alzheimer’s disease. This means all clinical data from the trial’s eight enrolled patients, including a wide range of biomarkers, have been collected, cleaned, and finalized, allowing formal statistical analysis to begin. The company expects topline results from this study in the first quarter of 2026. NeuroSense plans to share more information on the RoAD study and the expected readout timing during an investor webinar on December 8 at 08:30 EST.
NeuroSense Therapeutics Ltd. (NRSN) submitted a report stating that it has received FDA clearance to initiate a pivotal phase 3 clinical trial of its lead candidate PrimeC in amyotrophic lateral sclerosis (ALS). The update is provided through a press release furnished as an exhibit and is also incorporated by reference into several of the company’s existing registration statements. The filing itself does not include trial design details, timelines, or financial data, but signals that the program has advanced to a late-stage study under FDA oversight.
NeuroSense Therapeutics Ltd. (NRSN) submitted a Form 6-K as a foreign private issuer, mainly to furnish materials for an upcoming shareholder vote. The filing attaches a Notice and Proxy Statement for a special meeting of shareholders scheduled for December 30, 2025, along with a proxy card that shareholders can use to cast their votes.
The company also states that this Form 6-K is incorporated by reference into its existing shelf and employee benefit registration statements on Form S-8 and Form F-3. This linkage means the information in this report is now legally part of those registration statements, which can be relevant for future securities offerings and equity compensation plans.
NeuroSense Therapeutics Ltd. filed a Form F-3 to register 333,334 ordinary shares for resale by the selling shareholder. These shares were issued in a September 2025 private placement under a purchase agreement. We will not receive any proceeds from sales by the selling shareholder; they bear the sale decisions and receive all proceeds.
As context, the company had 29,550,970 ordinary shares outstanding as of October 27, 2025. The September 2025 private placement priced shares at $1.50 for gross proceeds of approximately $0.5 million. NeuroSense’s ordinary shares and warrants trade on Nasdaq as NRSN and NRSNW; on October 27, 2025, NRSN closed at $1.14. The prospectus permits various sale methods by the selling shareholder and does not obligate any sale.